Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report
Abstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correla...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-023-03804-5 |
_version_ | 1797864633038536704 |
---|---|
author | Tanawan Kongmalai Nalinee Chuanchaiyakul Yuttana Srinoulprasert Nuntakorn Thongtang |
author_facet | Tanawan Kongmalai Nalinee Chuanchaiyakul Yuttana Srinoulprasert Nuntakorn Thongtang |
author_sort | Tanawan Kongmalai |
collection | DOAJ |
description | Abstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correlate to the amount of proteinuria in nephrotic syndrome patients. Proprotein convertase subtilisin/kexin type 9 monoclonal antibody has been used to treat dyslipidemia in some refractory nephrotic syndrome cases. As a therapeutic protein, proprotein convertase subtilisin/kexin type 9 monoclonal antibody simply deteriorates if stored in inappropriate temperatures or conditions. Case presentation In this article, we present the case of a 16-year-old Thai female with severe combined dyslipidemia secondary to refractory nephrotic syndrome. She received proprotein convertase subtilisin/kexin type 9 monoclonal antibody (alirocumab) treatment. However, the drugs were mistakenly frozen in a freezer for up to 17 hours before being stored at 4 °C. After using two frozen devices, serum total cholesterol, free proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) significantly decreased. Nonetheless, the patient developed a skin rash 2 weeks after the second injection and the lesion spontaneously resolved without any treatment approximately 1 month later. Conclusions The effectiveness of proprotein convertase subtilisin/kexin type 9 monoclonal antibody seems to be stable after being stored under freeze–thaw conditions. However, improperly stored drugs should be discarded to avoid any potential undesirable side effects. |
first_indexed | 2024-04-09T22:55:02Z |
format | Article |
id | doaj.art-73718f4582cb4fee93e531e5abab6904 |
institution | Directory Open Access Journal |
issn | 1752-1947 |
language | English |
last_indexed | 2024-04-09T22:55:02Z |
publishDate | 2023-03-01 |
publisher | BMC |
record_format | Article |
series | Journal of Medical Case Reports |
spelling | doaj.art-73718f4582cb4fee93e531e5abab69042023-03-22T11:19:32ZengBMCJournal of Medical Case Reports1752-19472023-03-011711610.1186/s13256-023-03804-5Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case reportTanawan Kongmalai0Nalinee Chuanchaiyakul1Yuttana Srinoulprasert2Nuntakorn Thongtang3Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityAbstract Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/kexin type 9 levels directly correlate to the amount of proteinuria in nephrotic syndrome patients. Proprotein convertase subtilisin/kexin type 9 monoclonal antibody has been used to treat dyslipidemia in some refractory nephrotic syndrome cases. As a therapeutic protein, proprotein convertase subtilisin/kexin type 9 monoclonal antibody simply deteriorates if stored in inappropriate temperatures or conditions. Case presentation In this article, we present the case of a 16-year-old Thai female with severe combined dyslipidemia secondary to refractory nephrotic syndrome. She received proprotein convertase subtilisin/kexin type 9 monoclonal antibody (alirocumab) treatment. However, the drugs were mistakenly frozen in a freezer for up to 17 hours before being stored at 4 °C. After using two frozen devices, serum total cholesterol, free proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) significantly decreased. Nonetheless, the patient developed a skin rash 2 weeks after the second injection and the lesion spontaneously resolved without any treatment approximately 1 month later. Conclusions The effectiveness of proprotein convertase subtilisin/kexin type 9 monoclonal antibody seems to be stable after being stored under freeze–thaw conditions. However, improperly stored drugs should be discarded to avoid any potential undesirable side effects.https://doi.org/10.1186/s13256-023-03804-5Nephrotic syndromeDyslipidemiaPCSK9 monoclonal antibodyPCSK9 storageTemperatureCase report |
spellingShingle | Tanawan Kongmalai Nalinee Chuanchaiyakul Yuttana Srinoulprasert Nuntakorn Thongtang Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report Journal of Medical Case Reports Nephrotic syndrome Dyslipidemia PCSK9 monoclonal antibody PCSK9 storage Temperature Case report |
title | Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report |
title_full | Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report |
title_fullStr | Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report |
title_full_unstemmed | Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report |
title_short | Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report |
title_sort | injection of an improperly stored proprotein convertase subtilisin kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome a case report |
topic | Nephrotic syndrome Dyslipidemia PCSK9 monoclonal antibody PCSK9 storage Temperature Case report |
url | https://doi.org/10.1186/s13256-023-03804-5 |
work_keys_str_mv | AT tanawankongmalai injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport AT nalineechuanchaiyakul injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport AT yuttanasrinoulprasert injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport AT nuntakornthongtang injectionofanimproperlystoredproproteinconvertasesubtilisinkexintype9monoclonalantibodyinapatientwithsecondarydyslipidemiafromnephroticsyndromeacasereport |